| Bioactivity | CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1]. | ||||||||||||
| In Vivo | The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.)[1]. Animal Model: | ||||||||||||
| Name | CX516 | ||||||||||||
| CAS | 154235-83-3 | ||||||||||||
| Formula | C14H15N3O | ||||||||||||
| Molar Mass | 241.29 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 Nov;206(4):631-40. |